Page 2 - Biocon Biologic News Today

Eris Lifesciences has announced that it has reached a definitive agreement to acquire the dermatology and nephrology branded formulations business units of Biocon Biologics in India. The deal is valued at Rs 366 crore. The acquisition will be partially funded through debt financing.

Stocks to watch: Shares of firms like Tata Motors, SBI, Adani Wilmar, PB Fintech, IndiGo, Lupin, and others will be in focus on Thursday's trade.

USFDA: The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022 that the agency found to be adequate and indicated that it would require a re-inspection of the Malaysia facility prior to the approval of the application.

Get latest articles and stories on Latest News at LatestLY. Biotechnology major Biocon on Saturday said the US health regulator has issued a complete response letter for Biocon Biologics' application for Insulin Aspart, a proposed biosimilar for diabetes treatment. Latest News | USFDA Issues Complete Response Letter for Proposed Biosimilar Insulin Aspart: Biocon.

Bengaluru: Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced that the Company has completed the integration of the acquired biosimilars business from Viatris in North America...

Biocon Biologics has completed the integration of the acquired biosimilars business from Viatris in North America (United States and Canada) effective September 1 official statement said on Wednesday.To further strengthen its leadership ...

Biocon Biologics plans to complete the integration of Viatris biosimilar business in North America by the end of Q2FY24, which is ahead of the original transition plan. The early transition would enable the company to ramp up its business in North America more rapidly.

The investment, totaling Rs 1,070 crore, is set to facilitate Biocon Biologics acquisition of the biosimilars business of its partner, Viatris, , Competition Commission of India (CCI), kotak mahindra bank, Biocon Biologics, viatris, green channel, Approval

The investment will help Biocon Biologics acquisition of the biosimilars business of its partner Viatris.

Read the rationale behind our jury’s selection of South Asia’s FA Award winners.